Pharmaceutical composition containing pyridylaminoacetic acid compound

Abstract

The purpose of the present invention is to provide a pharmaceutical composition that comprises a specific compound and exhibits a superior preservation efficacy, the specific compound being stable within the pharmaceutical composition, and to provide methods for improving the stability of the specific compound within the pharmaceutical composition and the preservation efficacy of the pharmaceutical composition. The pharmaceutical composition according to the present invention comprises isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof, and further comprises edetic acid or a salt thereof.

1 . A pharmaceutical composition comprising isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof, which further comprises edetic acid or a salt thereof. 
     
     
         2 . A pharmaceutical composition comprising isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof and a nonionic surfactant, which further comprises edetic acid or a salt thereof. 
     
     
         3 . The pharmaceutical composition according to  claim 2 , wherein the nonionic surfactant includes polyoxyethylene castor oil, polyoxyethylene hardened castor oil, polyoxyethylene sorbitan fatty acid ester, or vitamin E TPGS. 
     
     
         4 . The pharmaceutical composition according to  claim 3 , wherein the polyoxyethylene castor oil includes polyoxyethylene castor oil selected from the group consisting of polyoxyl 5 castor oil, polyoxyl 9 castor oil, polyoxyl 15 castor oil, polyoxyl 35 castor oil, and polyoxyl 40 castor oil. 
     
     
         5 . The pharmaceutical composition according to  claim 3 , wherein the polyoxyethylene hardened castor oil includes polyoxyethylene castor oil selected from the group consisting of polyoxyethylene hardened castor oil 10, polyoxyethylene hardened castor oil 40, polyoxyethylene hardened castor oil 50, and polyoxyethylene hardened castor oil 60. 
     
     
         6 . The pharmaceutical composition according to  claim 3 , wherein the polyoxyethylene sorbitan fatty acid ester includes polyoxyethylene castor oil selected from the group consisting of Polysorbate 80, Polysorbate 60, Polysorbate 40, polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan trioleate, and Polysorbate 65. 
     
     
         7 . The pharmaceutical composition according to  claim 2 , wherein the content of the nonionic surfactant is in a range of 0.001 to 5% (w/v). 
     
     
         8 . The pharmaceutical composition according to  claim 7 , wherein the content of the nonionic surfactant is in a range of 0.8 to 2% (w/v). 
     
     
         9 . The pharmaceutical composition according to  claim 2 , wherein the content of the nonionic surfactant is in a range of 1 to 20,000 parts by mass relative to 1 part by mass of 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)isopropyl acetate or a salt thereof. 
     
     
         10 . The pharmaceutical composition according to  claim 1 , wherein the content of 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)isopropyl acetate or a salt thereof is in a range of 0.0001 to 0.1% (w/v). 
     
     
         11 . The pharmaceutical composition according to  claim 10 , wherein the content of 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)isopropyl acetate or a salt thereof is in a range of 0.001 to 0.003% (w/v). 
     
     
         12 . The pharmaceutical composition according to  claim 1 , wherein the content of edetic acid or a salt thereof is in a range of 0.001 to 1% (w/v). 
     
     
         13 . The pharmaceutical composition according to  claim 12 , wherein the content of edetic acid or a salt thereof is in a range of 0.01 to 0.1% (w/v). 
     
     
         14 . The pharmaceutical composition according to  claim 1 , wherein the content of edetic acid or a salt thereof is in a range of 0.1 to 1,000 parts by mass relative to 1 part by mass of 6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)isopropyl acetate or a salt thereof. 
     
     
         15 . The pharmaceutical composition according to  claim 1 , which further comprises boric acid or a salt thereof, citric acid or a salt thereof, or acetic acid or a salt thereof. 
     
     
         16 . The pharmaceutical composition according to  claim 1 , which does not comprise sorbic acid. 
     
     
         17 . The pharmaceutical composition according to  claim 1 , which is filled into a container made of polyethylene. 
     
     
         18 . The pharmaceutical composition according to  claim 1 , for prevention or treatment of glaucoma or ocular hypertension, or for reduction of intraocular pressure. 
     
     
         19 . A method for stabilizing isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof by allowing a pharmaceutical composition comprising isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof to comprise edetic acid or a salt thereof. 
     
     
         20 . A method for improving preservative effectiveness of a pharmaceutical composition comprising isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof by allowing the pharmaceutical composition to comprise edetic acid or a salt thereof.